🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great collaboration with Australian centres. Pleasure to be involved in this. Congratulations Christoph Seidel

Did not have ‘Running through herd of goats’ on my #ESMO2023 bingo card. But I guess that’s the beauty of Casa de Campo and Madrid. Until next time!

EV-Pembro is SOC for 1st line bladder cancer 50% of pts -> neuropathy Note phase 1 of EV monoRx 1mg/kg cohort: neuropathy 19%, ORR 19% 1.25mg/kg cohort: neuropathy 38%, ORR 43% Lesson: Don't dose reduce EV upfront Jonathan Rosenberg MD Daniel Petrylak shorturl.at/bKVWX

Everytime after a conference🫢🤣

Fantastic to be back in Chicago catching up on data, catching up with friends Laurence Albiges #ASCO24

Enthusiastic audience response to #ASCO24 plenary abstracts today. Great that the organisers were able to schedule Timmy Trumpet Tiësto Alesso for after party

🔍 AI in Oncology #ASCO2025 AI isn’t replacing oncologists—it’s augmenting care. Clinical decision support & ambient scribing to trial matching & drug discovery, AI improves efficiency, nudges evidence-based care, and supports overworked teams. Real challenge? Change management.

Real-world AI in cancer care: ✅ ↑ in end-of-life discussions via AI nudges ✅ Increase nurse time in care (↓ documentation) ✅ Faster trial screening & protein folding breakthroughs But trust lags behind tech. Transparency, bias control & safety need urgent attention. #AIOnc

What the #ASCO2025 AI session didn't cover fully (otherwise great talks) 1️⃣ Genomic + multi-omic integration platforms 2️⃣ Health equity & bias audit needs 3️⃣ Clinician AI training urgent 4️⃣ Medico-legal liability frameworks for use 5️⃣ Environmental costs of large models ?🔌☢️

#ASCO25 Drug development session: Is HER3 the new HER2—or is it too soon? 🧬 HER3-targeting ADCs show promise in NSCLC & SCLC, but biomarker gaps, resistance issues and payload limits remain. “It’s not too early, but it’s not yet.” Lillian Siu

🧬 New hope for GU neuroendocrine carcinomas: DLL3-targeted T-cell engager shows a 40% response rate & ~8mo durability in DLL3-high tumors— outperforming chemo or IO in this poor-prognosis group. Biomarker-driven therapy may be here for small cell GU. #ASCO25 #OncTwitter #GUonc

🧬 DYNAMIC-III shows ctDNA-guided chemo escalation in stage III colon cancer did not improve recurrence-free survival vs standard care. But ctDNA clearance post-chemo strongly predicts better outcomes. 40% pts persistent ctDNA despite chemo. Need new options #ASCO25 #CRC

🚨 KRAS G12C in CRC: Combo strategies evolving fast. 🧪 G12C inhibitors + anti-EGFR (e.g. cetuximab) show synergy (ORR ~46%) 💥 Adding chemo may boost activity—but ⏫ toxicity, dose interruptions 📌 Takeaways: – Drug exposure matters – ctDNA ≠ always concordant #ASCO25

🚨 Practice-changing data at #ASCO25 in #CRC 🔹 BREAKWATER: Encorafenib + cetuximab + FOLFOX doubles OS vs SOC (30.3 vs 15.1 mo) in BRAF V600E mCRC. 🔹 CheckMate 8HW: NIVO+IPI shows 54.1 mo PFS in MSI-H mCRC— new IO standard

5-yr data from KEYNOTE-564 confirms OS benefit for adjuvant #pembrolizumab in high-risk clear cell #RCC (HR 0.66). DFS & OS gains across subgroups. 🔥 Confirms OS benefit in adjuvant RCC 🧬 But are we overtreating 48% who never recur? #ASCO25 #GUonc #Immunotherapy

#SURE2: Sacituzumab + pembro: 44% CR and 71% bladder-intact EFS in MIBC patients refusing cystectomy ✂️ No chemo, no surgery 🔍 Biomarker-driven selection (luminal subtype, TMB) key? Are we ready to skip cystectomy? NMIBC recurrences an issue? urineDNA to confirm CR? #ASCO25

🚨 IO triplet in RCC hits turbulence Zanzalintinib + nivolumab = 63% ORR, 18.5 mo PFS ?benefit over Cabo/Nivo ?less HFS but similar activity... ➕ Adding relatlimab (triplet) ➡️ lower ORR & PFS 🔁 Rethink LAG3 as target RCC, it's not melanoma 😞 #ASCO25

🧵 Immune resistance in cancer 🛡️ T-cell exclusion? Target macrophages with PI3Kγ inhibitors (e.g. IPI-549) to open the tumor to immune attack. Chronic interferon = double-edged sword. JAK inhibition redirects exhausted T cells back into action. PD-1 + LAG-3 = durable IO ⚡